IRIDEX Corporation logo

IRIXIRIDEX Corporation

NASDAQ · Healthcare · Medical Devices

$0.72

-$0.01 (-0.97%)

IRIDEX Corporation (IRIX) is a medical devices company listed on NASDAQ. It is led by Patrick Mercer, based in 1212 Terra Bella Avenue, Mountain View, CA, United States, 94043, with about 93 employees. IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat uncontrolled and refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

Latest reported IRIX revenue for 2026-07-04 was $12.6M. Net income was -$1.3M. Revenue was down 48.4% from 2026-07-04 to 2026-07-04. IRIX currently screens at market cap $19.0M.

Use this IRIX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IRIX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IRIX SEC filings page. Lician reads the product cache first so this HTML stays unique to IRIDEX Corporation even when a live quote feed is slow.

About IRIDEX Corporation

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat uncontrolled and refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

IRIX Key Statistics

Market Cap

$18.97M

Volume

102,984

Previous Close

$0.75

Day Range

$0.72$0.76

00

EPS

-$0.26

Revenue

$52.67M

Net Income

-$4.44M

Gross Profit

$19.23M

Free Cash Flow

-$1.97M

Revenue Growth

+8.2%

Profit Margin

-8.4%

Debt to Equity

0.00

Employees

93

IRIX Financials

Annual income statement in USD. Latest reported periods first.

IRIX annual income statement across FY2026, FY2024
LineFY2026FY2024
Revenue$52.67M$48.67M
Cost of Revenue$33.45M$29.17M
Gross Profit$19.23M$19.50M
Operating Income-$2.57M-$8.30M
Net Income-$4.44M-$8.91M
EPS (Diluted)-$0.26-$0.54

Total Assets

$29.15M

Total Debt

$0.00

Shareholders' Equity

$4.92M

Cash & Equivalents

$6.03M

Operating Cash Flow

-$2.12M

Free Cash Flow

-$1.97M

IRIDEX Corporation Company Information

CEO, President & Director
Patrick Mercer
Headquarters
1212 Terra Bella Avenue, Mountain View, CA, United States, 94043
Phone
650 940 4700
IPO / Founded
1996-02-15
Industry
Medical Devices
Data Updated:

Upcoming Events for IRIX